Lakhdar H, Zouhair K, Khadir K, Essari A, Richard A, Seité S, Rougier A
University Teaching Hospital Ibn Rochd, Casablanca, Morocco.
J Eur Acad Dermatol Venereol. 2007 Jul;21(6):738-42. doi: 10.1111/j.1468-3083.2007.02185.x.
Chloasma, or melasma, is a pigmentary disorder that can affect between 50% and 70% of pregnant women. During pregnancy, chloasma does not require any particular treatment beside the use of an effective sunscreen and avoiding the use of any photosensitizing products or inappropriate skin care routine. However, there exist very few studies related to the benefits of sunscreens to prevent this dermatosis.
The aim of this study was to assess the role of a broad-spectrum sunscreen in the prevention and treatment of chloasma in pregnant women.
We tested the effectiveness and tolerance of a sunscreen composition (SPF 50+, UVA-PF 28) during a 12-month clinical trial on 200 parturients.
The 'excellent' tolerance of the sunscreen under evaluation was confirmed. Out of 185 patients who completed the study, only five new cases of chloasma were noted, an occurrence of 2.7%, which is much lower than the 53% previously observed in an usual condition study (same investigators, same geographical area and same time frame). In addition, the clinical effectiveness of the evaluated sunscreen was judged 'excellent' by the majority of parturients and by the research dermatologists during all the consultations. It is also worth noting that at 6 months, a clinical improvement was observed in 8 out of 12 volunteers who were affected by a pre-existing chloasma observed during their inclusion visit. Colorimetric measurements showed that, at the end of their pregnancy, the parturients' skin was, on average, significantly lightened (increase of parameter L* in 38% cases) and less pigmented (reduction of parameter b* in 50% cases); thus, resulting in a significantly lighter skin colour (increase of ITA degrees in 69% cases) compared to their inclusion visit.
This study clearly demonstrates the effectiveness of the well-tolerated broad-spectrum sunscreen evaluated, in the prevention of the development of chloasma in pregnant women.
黄褐斑,又称妊娠斑,是一种色素沉着紊乱疾病,可影响50%至70%的孕妇。在孕期,除使用有效的防晒霜并避免使用任何光敏产品或不当的皮肤护理程序外,黄褐斑无需特殊治疗。然而,关于防晒霜预防这种皮肤病的益处的研究非常少。
本研究旨在评估一款广谱防晒霜在预防和治疗孕妇黄褐斑中的作用。
我们在一项针对200名产妇的为期12个月的临床试验中测试了一种防晒霜组合物(防晒系数50+,UVA防护系数28)的有效性和耐受性。
所评估的防晒霜具有“极佳”的耐受性得到了证实。在完成研究的185名患者中,仅发现5例新的黄褐斑病例,发生率为2.7%,远低于先前在一项常规情况研究中观察到的53%(同一研究人员、相同地理区域和相同时间范围)。此外,大多数产妇和研究皮肤科医生在所有会诊中都认为所评估的防晒霜的临床效果“极佳”。还值得注意的是,在6个月时,12名在入组时就患有黄褐斑的志愿者中有8人出现了临床改善。比色测量显示,在妊娠末期,产妇的皮肤平均明显变浅(38%的病例中参数L增加)且色素沉着减少(50%的病例中参数b降低);因此,与入组时相比,皮肤颜色明显变浅(69%的病例中ITA度数增加)。
本研究清楚地证明了所评估的耐受性良好的广谱防晒霜在预防孕妇黄褐斑发展方面的有效性。